Axsome Therapeutics, Inc. (AXSM): Price and Financial Metrics

Axsome Therapeutics, Inc. (AXSM): $79.80

0.63 (+0.80%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

C

AXSM Price/Volume Stats

Current price $79.80 52-week high $98.40
Prev. close $79.17 52-week low $55.02
Day low $77.08 Volume 487,700
Day high $79.98 Avg. volume 771,220
50-day MA $83.84 Dividend yield N/A
200-day MA $75.54 Market Cap 3.78B

AXSM Stock Price Chart Interactive Chart >

AXSM POWR Grades

  • AXSM scores best on the Value dimension, with a Value rank ahead of 55.33% of US stocks.
  • AXSM's strongest trending metric is Sentiment; it's been moving down over the last 26 weeks.
  • AXSM's current lowest rank is in the Stability metric (where it is better than 1.69% of US stocks).

AXSM Stock Summary

  • With a price/sales ratio of 16.11, AXSOME THERAPEUTICS INC has a higher such ratio than 93.07% of stocks in our set.
  • With a year-over-year growth in debt of 96.73%, AXSOME THERAPEUTICS INC's debt growth rate surpasses 91.63% of about US stocks.
  • As for revenue growth, note that AXSM's revenue has grown 770.59% over the past 12 months; that beats the revenue growth of 98.96% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to AXSOME THERAPEUTICS INC are EKSO, CSTL, IRIX, QTRX, and WEAV.
  • Visit AXSM's SEC page to see the company's official filings. To visit the company's web site, go to www.axsome.com.

AXSM Valuation Summary

  • In comparison to the median Healthcare stock, AXSM's price/earnings ratio is 164.15% lower, now standing at -18.7.
  • AXSM's price/earnings ratio has moved down 3.7 over the prior 99 months.

Below are key valuation metrics over time for AXSM.

Stock Date P/S P/B P/E EV/EBIT
AXSM 2023-12-29 16.9 14.0 -18.7 -18.3
AXSM 2023-12-28 16.9 14.0 -18.7 -18.3
AXSM 2023-12-27 17.7 14.7 -19.6 -19.3
AXSM 2023-12-26 16.8 13.9 -18.6 -18.2
AXSM 2023-12-22 16.3 13.5 -18.0 -17.6
AXSM 2023-12-21 15.3 12.7 -17.0 -16.5

AXSM Growth Metrics

    The year over year net income to common stockholders growth rate now stands at -41.23%.
  • Its 5 year cash and equivalents growth rate is now at 338.28%.
  • The year over year price growth rate now stands at -37.41%.
AXSM's revenue has moved up $25,665,578 over the prior 33 months.

The table below shows AXSM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 25.66558 -117.7881 -159.8702
2022-06-30 8.819786 -121.8064 -149.9296
2022-03-31 0 -113.6633 -140.7753
2021-12-31 0 -108.2258 -130.403
2021-09-30 0 -99.93876 -125.5915
2021-06-30 0 -88.89714 -113.6336

AXSM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AXSM has a Quality Grade of C, ranking ahead of 33.39% of graded US stocks.
  • AXSM's asset turnover comes in at 0 -- ranking 441st of 682 Pharmaceutical Products stocks.
  • PPBT, TEVA, and PTE are the stocks whose asset turnover ratios are most correlated with AXSM.

The table below shows AXSM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 NA -3.694
2021-03-31 0 NA -4.444
2020-12-31 0 NA -8.032
2020-09-30 0 NA -22.741
2020-06-30 0 NA 38.093
2020-03-31 0 NA -3443.473

AXSM Price Target

For more insight on analysts targets of AXSM, see our AXSM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $86.21 Average Broker Recommendation 1.43 (Moderate Buy)

Axsome Therapeutics, Inc. (AXSM) Company Bio


Axsome Therapeutics Inc. focuses on developing therapies for the management of pain, neurological disorders, and other central nervous system. The company was founded in 2012 and is based in New York City, New York.


AXSM Latest News Stream


Event/Time News Detail
Loading, please wait...

AXSM Latest Social Stream


Loading social stream, please wait...

View Full AXSM Social Stream

Latest AXSM News From Around the Web

Below are the latest news stories about AXSOME THERAPEUTICS INC that investors may wish to consider to help them evaluate AXSM as an investment opportunity.

Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting

New data on Auvelity’s impact on quality of life, measured by the Q-LES-Q-SF, in patients who had received at least one prior treatment during their current depressive episode Data on Auvelity exploring reduction of depressive symptoms regardless of a patient’s interest-activity symptom severity NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (C

Yahoo | December 11, 2023

3 Unstoppable Stocks to Buy Right Now

Here's why they picked Axsome Therapeutics (NASDAQ: AXSM), Eli Lilly (NYSE: LLY), and Vertex Pharmaceuticals (NASDAQ: VRTX). David Jagielski (Axsome Therapeutics): One promising growth stock that investors may be overlooking today is Axsome Therapeutics. With a market capitalization of around $3.2 billion, this is still a fairly small biotech stock for investors to load up on before it gets much bigger.

Yahoo | December 10, 2023

Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today

NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, is hosting a virtual investor event and conference call today from 8 a.m. – 10 a.m. Eastern Time to provide an update on solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) and trace amine-associated receptor 1 (TAAR1) agonist. At the event, invited ph

Yahoo | December 7, 2023

11 Best Upside Stocks To Buy Right Now

In this piece, we will take a look at the 11 best upside stocks to buy right now. If you want to skip our overview of share valuation, then take a look at the 5 Best Upside Stocks To Buy Now. The art of buying shares on the market has always gone hand in hand […]

Yahoo | November 27, 2023

Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7

NEW YORK, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will host a virtual event on December 7 from 8 a.m. - 10 a.m. Eastern Time to provide investors an update on its development programs for solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor and trace amine-associated receptor 1 (TAAR1)

Yahoo | November 22, 2023

Read More 'AXSM' Stories Here

AXSM Price Returns

1-mo -5.00%
3-mo 0.26%
6-mo 14.18%
1-year 27.80%
3-year 39.32%
5-year 460.79%
YTD 0.26%
2023 3.19%
2022 104.16%
2021 -53.63%
2020 -21.18%
2019 3,565.25%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!